AG019 / Precigen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AG019 / Precigen
2017-002871-24: A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)

Not yet recruiting
1/2
48
Europe
AG019, Teplizumab, Gastro-resistant capsule, hard, Solution for infusion
Intrexon T1D Partners, LLC (IT1D), IT1D
Recent-onset Type 1 Diabetes mellitus (T1D), Recent-onset Type 1 Diabetes mellitus (T1D), Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 

Download Options